October 01, 2025

Remibrutinib Gains FDA Nod for Urticaria

First oral BTK inhibitor approved for antihistamine-resistant chronic spontaneous urticaria, targeting mast cell–driven immune dysregulation

Conexiant

September 29, 2025

FDA Expands Options for Pediatric Psoriasis, PsA

The FDA has approved the first IL-23 inhibitor for pediatric patients with plaque psoriasis and psoriatic arthritis.

Conexiant

April 29, 2024

Exposed to Agent Orange at US Bases, Veterans Face Cancer Without VA Compensation

A veteran's struggle for recognition of health issues linked to exposure to a controversial herbicide used by the military.

KFF Health News

May 07, 2024

What’s Keeping the US From Allowing Better Sunscreens?

Examine the FDA's stringent sunscreen regulations and the impact on the availability of advanced sunscreen ingredients in the U.S., as well as bipartisan legislative efforts to modernize these standards.

KFF Health News

April 29, 2024

Record Heat Waves Propel Surge in Heat-Related Illness

2023 brought record-breaking heat waves in the United States, significantly impacting vulnerable groups. Analysis by the CDC revealed a substantial number of heat-related illness (HRI) emergency department visits, resulting in multiple public health alerts.

Conexiant

July 24, 2024

World Bank's Pandemic Fund Raises $700M from U.S., Germany

The World Bank's Pandemic Fund secures substantial contributions from the U.S. and Germany, aiming to prevent a recurrence of a crisis similar to COVID-19.

Reuters

November 15, 2024

RFK Jr.'s Vision for U.S. Food and Drug System Reform

The FDA's nutrition department has to go: "They're not doing their job. They're not protecting our kids."

Reuters

January 15, 2025

Bertagnolli to Exit NIH Director Role

NIH director, Dr. Monica M. Bertagnolli, is stepping down after launching major initiatives in women's health and long COVID research, indicating optimism for their continuation under new leadership.

Conexiant

April 18, 2025

FDA Approves New Spontaneous Urticaria Therapy

The FDA approved dupilumab as the first targeted therapy for chronic spontaneous urticaria in patients aged 12 years and older uncontrolled on antihistamines.

Conexiant